BGI Genomics：华大基因（300676）：Expense Ratios and GPM Dented Net Profit in 1Q25-20250529

Equity Research Report BGI Genomics (300676 CH) Expense Ratios and GPM Dented Net Profit in 1Q25 | Huatai Research | Annual Results Review | Rating (Maintain): | OVERWEIGHT | | --- | --- | --- | --- | | 29 May 2025 │ China (Mainland) | Medical Devices | Target price (RMB): | 52.19 | BGI Genomics' revenue/attributable net profit (NP)/recurring attributable NP were RMB+3,867/-903/-919mn (-11.1/-1,072/-1,091% yoy) for 2024 and RMB+672/-53/-63mn (-18/-525/-2,879% yoy) for 1Q25. Its 2024 revenue/attributable NP ...